Treats migraine attacks with or without aura. ANDA 218011, held by Taro. Diclofenac Potassium.
As of Nov 16, 2026, ANDA 218011 (Diclofenac Potassium), held by Taro, was first approved by FDA on Jun 14, 2024, with 0 approved supplements and 0 published complete response letters.
Diclofenac potassium for oral solution is indicated for the acute treatment of migraine attacks with or without aura in adults (18 years of age or older).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 14, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Potassium50MG · for solution;oral | Diclofenac Potassium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters